New antibiotic under the microscope: can it beat superbug infections?
NCT ID NCT07601711
First seen May 24, 2026 · Last updated Jun 17, 2026 · Updated 6 times
Summary
This study is observing 200 hospitalized adults with carbapenem-resistant Acinetobacter baumannii (CRAB) infections—a type of superbug—who are treated with the antibiotic sulbactam-durlobactam. Researchers will compare their outcomes to patients receiving other treatments to see if the new drug is more effective and safe. The goal is to gather real-world evidence to guide better treatment decisions for these serious infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.